Curing APL through PML/RARA degradation by As2O3

Trends in Molecular Medicine

Volumn 18, Issue 1, 2012, Pages 36-42

  Lallemand Breitenbach, Valerie ^a,b,c   Zhu, Jun ^c,d   Chen, Zhu ^d,e   De Thé, Hugues ^a,b,c,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Universitaire d'Hématologie   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BCR ABL PROTEIN; CBL PROTEIN; CYCLIC AMP; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; SUMO PROTEIN; TAX PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE RNF4; UNCLASSIFIED DRUG;

BINDING SITE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DISEASE CONTROL; DNA DAMAGE; DRUG TARGETING; EX VIVO STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; IN VIVO STUDY; LEUKEMIA REMISSION; NONHUMAN; OXIDATION; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MULTIMERIZATION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; OXIDES; SUMOYLATION; TREATMENT OUTCOME;

EID: 84855577308     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.10.001     Document Type: Review

References (72)

1. Zhu J., et al. How acute promyelocytic leukemia revived arsenic. Nat. Rev. Cancer 2002, 2:705-713.
2. Chen S.J., et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011, 117:6425-6437.
3. Jeanne M., et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010, 18:88-98.
4. Zhang X.W., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
5. Kogan S.C. Medicine. Poisonous contacts. Science 2010, 328:184-185.
6. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
7. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5328-5335.
8. Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia. Blood 2009, 114:5126-5135.
9. Estey E., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469-3473.
10. de The H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 2010, 10:775-783.
11. Ablain J., et al. Oncoprotein proteolysis, an unexpected Achille's heel of cancer cells?. Cancer Discov. 2011, 1:117-127.
12. Akagi T., et al. Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 2009, 113:1741-1748.
13. Wartman L.D., et al. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J. Clin. Invest. 2011, 121:1445-1455.
14. Jones L., et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J. Exp. Med. 2010, 207:2581-2594.
15. Kamashev D.E., et al. PML/RARA-RXR oligomers mediate retinoid- and rexinoid/cAMP in APL cell differentiation. J. Exp. Med. 2004, 199:1-13.
16. Martens J.H., et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010, 17:173-185.
17. Lallemand-Breitenbach V., de The H. PML nuclear bodies. Cold Spring Harb. Perspect. Biol. 2010, 2:a000661.
18. Gottifredi V., Prives C. P53 and PML: new partners in tumor suppression. Trends Cell Biol. 2001, 11:184-187.
19. Pearson M., et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000, 406:207-210.
20. Ito K., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078.
21. Regad T., et al. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat. Neurosci. 2009, 12:132-140.
22. Zhao Z., et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010, 24:1389-1402.
23. Cicalese A., et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.
24. Zhou J., et al. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9238-9243.
25. Zhu J., et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14807-14812.
26. Cassinat B., et al. New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor alpha recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation. Mol. Cell. Biol. 2011, 31:1409-1418.
27. Nasr R., et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008, 14:1333-1342.
28. Kogan S.C. Curing APL: differentiation or destruction?. Cancer Cell 2009, 15:7-8.
29. Ablain J., de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011, 117:5795-5802.
30. Tsimberidou A.M., et al. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M.D. Anderson Cancer Center Series. Leuk. Lymphoma 2006, 47:1062-1068.
31. Mathews V., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J. Clin. Oncol. 2010, 28:3866-3871.
32. Ghavamzadeh A., et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J. Clin. Oncol. 2011, 29:2753-2757.
33. Miller W.H., et al. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
34. Zhu X.H., et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. 1999, 91:772-778.
35. Zhu J., et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3978-3983.
36. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
37. Lallemand-Breitenbach V., et al. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat. Rev. Cancer 2005, 5:821-827.
38. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10173-10178.
39. Sanz M.A., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
40. Zheng P.Z., et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7653-7658.
41. Camacho L.H., et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol. 2000, 18:2620-2625.
42. Guillemin M.C., et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 2002, 196:1373-1380.
43. Zhu J., et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007, 12:23-35.
44. Isakson P., et al. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010, 116:2324-2331.
45. Shao W., et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARalpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 1998, 90:124-133.
46. Jing Y., et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001, 97:264-269.
47. Hu J., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3342-3347.
48. Geoffroy M.C., Hay R.T. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat. Rev. Mol. Cell Biol. 2009, 10:564-568.
49. Lallemand-Breitenbach V., et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 2001, 193:1361-1372.
50. Lallemand-Breitenbach V., et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 2008, 10:547-555.
51. Tatham M.H., et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 2008, 10:538-546.
52. Kawata K., et al. Classification of heavy-metal toxicity by human DNA microarray analysis. Environ. Sci. Technol. 2007, 41:3769-3774.
53. Goto E., et al. Missense mutations in PML-RARA critical for the lack of responsiveness to arsenic trioxide treatment. Blood 2011, 118:1600-1609.
54. Freitas R.A., et al. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. Leuk. Res. 2009, 33:958-963.
55. Dos Santos G.A., et al. (+)alpha-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia 2011, 10.1038/leu.2011.216.
56. Rego E.M., et al. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 2001, 193:521-530.
57. Gurrieri C., et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 2004, 103:2358-2362.
58. Yin T., et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004, 104:4219-4225.
59. Mao J.H., et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21683-21688.
60. Bazarbachi A., et al. How I treat adult T-cell leukemia/lymphoma. Blood 2011, 118:1736-1745.
61. El-Sabban M.E., et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappaB activation. Blood 2000, 96:2849-2855.
62. El Hajj H., et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J. Exp. Med. 2010, 207:2785-2792.
63. Kchour G., et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532.
64. Bernardi R., Pandolfi P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 2007, 8:1006-1016.
65. Winkel L.H., et al. Arsenic pollution of groundwater in Vietnam exacerbated by deep aquifer exploitation for more than a century. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1246-1251.
66. Soignet S.L., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 2001, 19:3852-3860.
67. Moilanen A.M., et al. Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol. Cell. Biol. 1998, 18:5128-5139.
68. Hakli M., et al. Transcriptional coregulator SNURF (RNF4) possesses ubiquitin E3 ligase activity. FEBS Lett. 2004, 560:56-62.
69. Sun H., et al. Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 2007, 26:4102-4112.
70. Prudden J., et al. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 2007, 26:4089-4101.
71. Shen T.H., et al. The mechanisms of PML-nuclear body formation. Mol. Cell 2006, 24:331-339.
72. Muller S., et al. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 1998, 17:61-70.